Cory White, MD
Endocrinology, Diabetes & Metabolism · Greenville, SCNPI 1700973765
Payments from drug & device makers
Across 1,259 payments — averaging $327.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$363K
- Boehringer Ingelheim$38K
- AbbVie$4K
- AstraZeneca$778
- Sanofi-aventis U.S. LLC$522
- Dexcom, Inc.$512
- plus $5K from 38 others
What the payments were for
- Consulting fees$6,1751%
- Speaking & faculty fees$380,50092%
- Travel & lodging$11,7803%
- Food & beverage$14,1293%
- Education$1030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$201,817
- TRULICITY$101,003
- JARDIANCE$84,535
- Synthroid$3,025
- DEXCOM G7 GSS (161)$120
How this compares
$412,687 in reported general payments places this provider in the 90th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
See all endocrinology, diabetes & metabolism providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 168 | $331,488 |
| OzempicSemaglutide | 104 | $172,982 |
| JardianceEmpagliflozin | 70 | $107,194 |
| Tresiba Flextouch U-200Insulin Degludec | 46 | $90,974 |
| FarxigaDapagliflozin Propanediol | 63 | $77,027 |
| TrulicityDulaglutide | 58 | $74,289 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 18 | $63,383 |
| SynthroidLevothyroxine Sodium | 355 | $37,026 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $35,218 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $35,201 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $28,676 |
| Humalog Kwikpen U-100Insulin Lispro | 30 | $19,049 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 18 | $16,882 |
| VascepaIcosapent Ethyl | 15 | $14,649 |
| Novolog FlexpenInsulin Aspart | 41 | $12,511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $363,239 | $407,728237 claims |
| Novo NordiskOzempic, Novolog | $351 | $177,221117 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $38,370 | $124,07588 claims |
| AstraZenecaFarxiga | $778 | $77,02763 claims |
| AbbVieSynthroid | $4,449 | $37,026355 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $241 | $12,177975 claims |
| IBSA Pharma Inc.Tirosint | $215 | $3,12326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
Other endocrinology, diabetes & metabolism in Greenville
- Sandra WeberGreenville$187K
- James HortonGreenville$73K
- John BruchGreenville$25K
- Maximilien RappaportGreenville$17K
- Mojgan RahmaniyanGreenville$6K
- Ronald MayfieldSpartanburg$8.9M
- Donald EagertonMyrtle Beach$7.9M
- Beatrice HullCharleston$987K
- Anne LarochelleMyrtle Beach$678K
- Gauri DhirMyrtle Beach$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.